VBIV - VBI Vaccines Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

VBI Vaccines Inc.

222 Third Street
Suite 2241
Cambridge, MA 02142
United States

Full Time Employees108

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey R. Baxter F.C.M.A., FCMAPres, CEO & Director780.27kN/A1961
Dr. David Evander AndersonChief Scientific Officer461.14kN/A1970
Dr. Francisco Diaz-MitomaChief Medical Officer530.89kN/A1955
Mr. Christopher McNultyCFO, Head of Bus. Devel. & DirectorN/AN/A1977
Ms. Athena KartsaklisSr. VP of Fin., Chief Compliance Officer & Principal Financial OfficerN/AN/A1965
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus. It is also developing cytomegalovirus vaccine candidate for infectious disease; and glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts.

Corporate Governance

VBI Vaccines Inc.’s ISS Governance QualityScore as of December 2, 2019 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.